

**SUPPLEMENT No. 11 DATED 14 APRIL 2026 TO THE BASE PROSPECTUS DATED 17 APRIL 2025 AND TO EACH OF THE FINAL TERMS DATED 24 FEBRUARY 2026, 17 MARCH 2026, 25 MARCH 2026, 26 MARCH 2026, 1 APRIL 2026 AND 9 APRIL 2026**

# J.P.Morgan

**J.P. Morgan Structured Products B.V.**  
*(incorporated with limited liability in The Netherlands)*

as Issuer

**JPMorgan Chase Financial Company LLC**  
*(incorporated with limited liability in the State of Delaware, United States of America)*

as Issuer

**JPMorgan Chase Bank, N.A.**  
*(a national banking association organised under the laws of the United States of America)*

as Issuer and as Guarantor in respect of Securities  
issued by  
J.P. Morgan Structured Products B.V.

**JPMorgan Chase & Co.**  
*(incorporated in the State of Delaware, United States of America)*

as Issuer and as Guarantor in respect of Securities  
issued by  
JPMorgan Chase Financial Company LLC

**Structured Securities Programme for the issuance**

**of**

**Notes, Warrants and Certificates**

*Arranger and Dealer for the Programme*

**J.P. Morgan**

## Supplement to the Base Prospectus

This supplement (the "**Supplement**") constitutes a supplement to the base prospectus dated 17 April 2025 (the "**Original Base Prospectus**"), as supplemented by Supplement No. 1 dated 15 May 2025, Supplement No. 2 dated 19 June 2025 to the Base Prospectus in respect of the Final Terms dated 13 May 2025, Supplement No. 3 dated 29 July 2025, Supplement No. 4 dated 21 August 2025, Supplement No. 5 dated 11 September 2025, Supplement No. 6 dated 2 October 2025 to the Base Prospectus in respect of the Final Terms dated 19 September 2025, Supplement No. 7 dated 30 October 2025, Supplement No. 8 dated 20 November 2025, Supplement No. 9 dated 29 January 2026 and Supplement No. 10 dated 26 February 2026 (the Original Base Prospectus, as so supplemented, the "**Base Prospectus**"), which constitutes four base prospectuses for the purposes of Article 8 of Regulation (EU) 2017/1129 (the "**Prospectus Regulation**"): (i) a base prospectus in respect of J.P. Morgan Structured Products B.V. ("**JPMSP**") (the "**JPMSP Base Prospectus**"), (ii) a base prospectus in respect of JPMorgan Chase Bank, N.A. (the "**JPMorgan Chase Bank, N.A. Base Prospectus**"), (iii) a base prospectus in respect of JPMorgan Chase & Co. (the "**JPMorgan Chase & Co. Base Prospectus**") and (iv) a base prospectus in respect of JPMorgan Chase Financial Company LLC ("**JPMCFC**") (the "**JPMCFC Base Prospectus**"), in each case, prepared in connection with the issue of non-equity securities under the Structured Securities Programme for the issuance of Notes, Warrants and Certificates (the "**Programme**") by JPMSP, JPMorgan Chase Bank, N.A., JPMorgan Chase & Co. and JPMCFC, irrevocably guaranteed in respect of Securities issued by JPMSP as to payment, delivery and other obligations by JPMorgan Chase Bank, N.A. and in respect of Securities issued by JPMCFC as to payment, delivery and other obligations by JPMorgan Chase & Co. Terms defined in the Base Prospectus have the same meanings when used in this Supplement. This Supplement constitutes a supplement to, and should be read in conjunction with, the JPMSP Base Prospectus, the JPMorgan Chase Bank, N.A. Base Prospectus, the JPMorgan Chase & Co. Base Prospectus and the JPMCFC Base Prospectus.

This Supplement also constitutes a supplement to:

- the Final Terms dated 24 February 2026 relating to the issue of EUR 30,000,000 Six-Year Autocallable Barrier Reverse Convertible Notes linked to the Ordinary Shares of Kering SA, due May 2032 (ISIN: FR0014016BP6) issued under the Programme by JPMSP pursuant to the JPMSP Base Prospectus (the "**JPMSP Final Terms dated 24 February 2026 (ISIN: FR0014016BP6)**");
- the Amended and Restated Final Terms dated 17 March 2026 (amending and restating the Final Terms dated 17 February 2026) relating to the issue of EUR 30,000,000 Twelve-Year Autocallable Barrier Reverse Convertible Notes linked to the Euro iStoxx® 50 Equal Weight NR Decrement 5% Index, due May 2038 (ISIN: FR0014015FZ8) issued under the Programme by JPMSP pursuant to the JPMSP Base Prospectus (the "**JPMSP Final Terms dated 17 March 2026 (ISIN: FR0014015FZ8)**");
- the Final Terms dated 25 March 2026 relating to the issue of up to EUR 100,000,000 Notes linked to a Weighted Basket of Shares, due May 2030 (ISIN: XS3015321568) issued under the Programme by JPMSP pursuant to the JPMSP Base Prospectus (the "**JPMSP Final Terms dated 25 March 2026 (ISIN: XS3015321568)**");
- the Amended and Restated Final Terms dated 25 March 2026 (amending and restating the Final Terms dated 12 February 2026) relating to the issue of EUR 30,000,000 Twelve-Year Autocallable Barrier Reverse Convertible Notes linked to the Euronext Transatlantic PAB 50 Decrement 5% Index, due June 2038 (ISIN: FR0014015DE8) issued under the Programme by JPMSP pursuant to the JPMSP Base Prospectus (the "**JPMSP Final Terms dated 25 March 2026 (ISIN: FR0014015DE8)**");
- the Amended and Restated Final Terms dated 25 March 2026 (amending and restating the Final Terms dated 12 February 2026) relating to the issue of EUR 30,000,000 Twelve-Year Autocallable Barrier Reverse Convertible Notes linked to the Euronext Transatlantic PAB 50

Decrement 5% Index, due June 2038 (ISIN: FR0014015DF5) issued under the Programme by JPMSP pursuant to the JPMSP Base Prospectus (the "**JPMSP Final Terms dated 25 March 2026 (ISIN: FR0014015DF5)**");

- the Amended and Restated Final Terms dated 25 March 2026 (amending and restating the Final Terms dated 12 February 2026) relating to the issue of EUR 30,000,000 12-Year Autocallable Phoenix Notes linked to Solactive BUND 10Y 11am Yield Index, due June 2038 (ISIN: XS3015336087) issued under the Programme by JPMSP pursuant to the JPMSP Base Prospectus (the "**JPMSP Final Terms dated 25 March 2026 (ISIN: XS3015336087)**");
- the Final Terms dated 25 March 2026 relating to the issue of EUR 30,000,000 12-Year Autocallable Phoenix Notes linked to TEC 10, due June 2038 (ISIN: FR0014016PG5) issued under the Programme by JPMSP pursuant to the JPMSP Base Prospectus (the "**JPMSP Final Terms dated 25 March 2026 (ISIN: FR0014016PG5)**");
- the Final Terms dated 26 March 2026 relating to the issue of up to SEK 500,000,000 Three-Year Participation Notes linked to the STOXX Europe 600 Index, due May 2029 (ISIN: SE0028329318) issued under the Programme by JPMSP pursuant to the JPMSP Base Prospectus (the "**JPMSP Final Terms dated 26 March 2026 (ISIN: SE0028329318)**");
- the Final Terms dated 26 March 2026 relating to the issue of up to SEK 500,000,000 Six-Year Participation Notes linked to the STOXX Europe 600 Health Care Index and NOKSEK, due May 2032 (ISIN: SE0028329326) issued under the Programme by JPMSP pursuant to the JPMSP Base Prospectus (the "**JPMSP Final Terms dated 26 March 2026 (ISIN: SE0028329326)**");
- the Final Terms dated 26 March 2026 relating to the issue of up to SEK 500,000,000 Six-Year Participation Notes linked to the STOXX Europe 600 Health Care Index and NOKSEK, due May 2032 (ISIN: SE0028329342) issued under the Programme by JPMSP pursuant to the JPMSP Base Prospectus (the "**JPMSP Final Terms dated 26 March 2026 (ISIN: SE0028329342)**");
- the Final Terms dated 26 March 2026 relating to the issue of up to SEK 500,000,000 Six-Year Participation Notes linked to the OMX Stockholm 30 Index, due May 2032 (ISIN: SE0028329334) issued under the Programme by JPMSP pursuant to the JPMSP Base Prospectus (the "**JPMSP Final Terms dated 26 March 2026 (ISIN: SE0028329334)**");
- the Final Terms dated 1 April 2026 relating to the issue of up to 10,000 7-Year Autocallable Phoenix Certificates linked to the Solactive BTP 10Y Annual Comp. 11am Yield Index, due April 2033 (ISIN: XS3015640157) issued under the Programme by JPMSP pursuant to the JPMSP Base Prospectus (the "**JPMSP Final Terms dated 1 April 2026 (ISIN: XS3015640157)**"); and
- the Final Terms dated 9 April 2026 relating to the issue of up to EUR 10,000,000 1-Year 11.00% p.a. Autocallable Barrier Reverse Convertible Notes, linked to the ordinary share of Enel S.p.A, the ordinary share of Iberdrola S.A. and the ordinary share of RWE AG, due at the latest on 30 April 2027 (ISIN: DE000JE2WCY0) issued under the Programme by JPMSP pursuant to the JPMSP Base Prospectus (the "**JPMSP Final Terms dated 9 April 2026 (ISIN: DE000JE2WCY0)**").

### **Purpose of Supplement**

The purpose of this Supplement is to:

- (a) incorporate by reference into the Base Prospectus the JPMSP 2025 Annual Report, the JPMCFC 2025 Audited Financial Statements, the JPMorgan Chase & Co. 2026 Proxy Statement, the

Supplement No. 3 to the Registration Document of JPMSP and the Supplement No. 9 to the Registration Document of JPMCFC (each as defined below); and

- (b) amend and supplement the information in the Summary of each of the JPMSP Final Terms dated 24 February 2026 (ISIN: FR0014016BP6), JPMSP Final Terms dated 17 March 2026 (ISIN: FR0014015FZ8), JPMSP Final Terms dated 25 March 2026 (ISIN: XS3015321568), JPMSP Final Terms dated 25 March 2026 (ISIN: FR0014015DE8), JPMSP Final Terms dated 25 March 2026 (ISIN: FR0014015DF5), JPMSP Final Terms dated 25 March 2026 (ISIN: XS3015336087), JPMSP Final Terms dated 25 March 2026 (ISIN: FR0014016PG5), JPMSP Final Terms dated 26 March 2026 (ISIN: SE0028329318), JPMSP Final Terms dated 26 March 2026 (ISIN: SE0028329326), JPMSP Final Terms dated 26 March 2026 (ISIN: SE0028329342); JPMSP Final Terms dated 26 March 2026 (ISIN: SE0028329334), JPMSP Final Terms dated 1 April 2026 (ISIN: XS3015640157) and JPMSP Final Terms dated 9 April 2026 (ISIN: DE000JE2WCY0).

#### **Right to withdraw acceptances**

**In accordance with Article 23(2) of the Prospectus Regulation, investors in the European Economic Area who have already agreed to purchase or subscribe for Securities issued under the Base Prospectus before this Supplement is published and where the Securities have not yet been delivered to them at the time when the significant new factor, material mistake or material inaccuracy to which this Supplement relates arose or was noted have the right, exercisable within three working days after the publication of this Supplement, to withdraw their acceptances. This right is exercisable up to, and including 17 April 2026. Investors may contact the relevant Authorised Offeror(s) (as set out in the Final Terms of the relevant Securities) should they wish to exercise such right of withdrawal.**

#### **Status of Supplement**

The Supplement is a supplement for the purposes of Article 23(1) of the Prospectus Regulation. On 17 April 2025, the *Commission de Surveillance du Secteur Financier* (the "**CSSF**") approved the Base Prospectus for the purposes of Article 6 of the Luxembourg Law dated 16 July 2019 on prospectuses for securities. The amendments included in this Supplement to the terms and conditions of the Securities shall only apply to Final Terms, the date of which falls on or after the approval of this Supplement (save where the Final Terms provide that the terms and conditions of the Securities are to be incorporated from an earlier base prospectus).

The Supplement has also been approved by the Luxembourg Stock Exchange pursuant to the rules and regulations of the Luxembourg Stock Exchange for the Euro MTF Market in respect of Exempt Securities.

#### **Responsibility**

In relation to the JPMSP Base Prospectus and the JPMorgan Chase Bank, N.A. Base Prospectus, JPMorgan Chase Bank, N.A. accepts responsibility for the information given in this Supplement and confirms that, to the best of its knowledge, the information contained in this Supplement is in accordance with the facts and makes no omission likely to affect its import. In relation to the JPMorgan Chase & Co. Base Prospectus and the JPMCFC Base Prospectus, JPMorgan Chase & Co. accepts responsibility for the information given in this Supplement and confirms that, to the best of its knowledge, the information contained in this Supplement is in accordance with the facts and makes no omission likely to affect its import.

## Information being supplemented

### I. Incorporation by reference

This Supplement incorporates by reference into the Base Prospectus:

- (a) the JPMSP Annual Report for the year ended 31 December 2025 (the "**JPMSP 2025 Annual Report**") (available at <https://dl.luxse.com/dlp/109b8652f5a7e749eb84812b151829b3b8>);
- (b) the audited financial statements of JPMCFC as at 31 December 2025 and 2024 and for each of the two years in the period ended 31 December 2025 (the "**JPMCFC 2025 Audited Financial Statements**") (available at <https://dl.luxse.com/dlp/101f0ed3a02ae747749ce1457e357fa256>);
- (c) the Proxy Statement on Schedule 14A of JPMorgan Chase & Co. dated 6 April 2026 as filed with the United States Securities and Exchange Commission (the "**JPMorgan Chase & Co. 2026 Proxy Statement**") (available at <https://dl.luxse.com/dlp/105cb5197e1aab4566b0281fabf3ecd9a9>);
- (d) Supplement No. 3 dated 13 April 2026 to the Registration Document dated 16 April 2025 of J.P. Morgan Structured Products B.V. ("**Supplement No. 3 to the Registration Document of JPMSP**") (available at <https://dl.luxse.com/dlp/106c91b8b5266c453ba97a12d40964030e>); and
- (e) Supplement No. 9 dated 13 April 2026 to the Registration Document dated 16 April 2025 of JPMorgan Chase Financial Company LLC ("**Supplement No. 9 to the Registration Document of JPMCFC**") (available at <https://dl.luxse.com/dlp/108daf3eb194ca4f329c8bc444861d414f>).

A copy of each of these documents has been filed with the CSSF in its capacity as competent authority under Article 31(1) of the Prospectus Regulation and, by virtue of this Supplement, the information set out in the sections of each document referred to below is incorporated by reference into and forms part of the Base Prospectus.

Information incorporated by reference	Page Reference
<b><i>From the JPMSP 2025 Annual Report*</i></b>	
Directors' report	3 to 10
Financial statements:	
Statement of financial position	11
Income statement	12
Statement of comprehensive income	12
Statement of changes in equity	13
Statement of cash flows	14
Notes to the financial statements	15 to 40
Other Information:	
Profit appropriation according to the Articles of Association	41
Independent auditors' report**	42 to 49
<b><i>From the JPMCFC 2025 Audited Financial Statements</i></b>	
Board of Managers' Report	1 to 6
Report of Independent Auditors	7 to 8
Financial Statements	
Statements of Financial Condition	9
Statements of Income/(Loss) and Comprehensive Income /(Loss)	10
Statements of Changes in Member's Equity	11
Statements of Cash Flows	12
Notes to Financial Statements	13 to 24

<i><b>From the JPMorgan Chase &amp; Co. 2026 Proxy Statement</b></i>		
<i>Corporate Governance</i>	<b>Proposal 1: Election of Directors</b>	7
	Key factors for shareholder consideration	8
	Director nominees	9 to 20
	Board governance	21 to 27
	Board oversight	28 to 29
	Engagement	30 to 31
	Director compensation	32 to 33
	Other corporate governance policies and practices	34 to 37
<i>Executive Compensation</i>	<b>Proposal 2: Advisory resolution to approve executive compensation</b>	38
	Compensation Discussion and Analysis	39
	Introduction & Overview	39 to 42
	1. How we think about pay decisions	43 to 52
	2. How we performed against our business strategy	53 to 55
	3. How performance determined pay in 2025	56 to 61***
	Compensation & Management Development Committee report	62
	Executive compensation tables	63
	I. Summary compensation table (SCT)	63 to 64
	II. 2025 Grants of plan-based awards	64
	III. Outstanding equity awards at fiscal year-end 2025	65 to 66
	IV. 2025 Option exercises and stock vested table	67
	V. 2025 Pension benefits	67 to 68
	VI. 2025 Non-qualified deferred compensation	68
	VII. 2025 Potential payments upon termination or change in control	69 to 70
	Pay versus performance disclosure	71 to 73***
	CEO pay ratio disclosure	74
	Security ownership of directors and executive officers	75 to 76
<i>Audit Matters</i>	<b>Proposal 3: Ratification of independent registered public accounting firm</b>	77
	Overview	77
	Engagement of independent registered public accounting firm	78
	Board oversight of PwC	78
	Fees paid to PricewaterhouseCoopers LLP	79
	Audit Committee approval policy and procedures	79
	Audit Committee report	80 to 81
<i>Shareholder Proposals</i>	<b>Proposal 4 – 7: Shareholder-submitted proposals</b>	82
	Introduction	83
	4. Report on congruence of security, resiliency, and climate initiatives	84 to 85
	5. Independent board chairman	86 to 88
	6. Lobbying alignment	89 to 90
	7. Sustainability ROI report	91 to 93
<i>General Information</i>	<b>Information About the Annual Shareholder Meeting</b>	94 to 100
	<b>Shareholder Proposals and Nominations for the 2027 Annual Meeting</b>	101 to 102
	<b>Notes on Non-GAAP Financial Measures</b>	103 to 104

***From Supplement No. 3 to the Registration Document of JPMSP***

Amendments to the information contained in the Registration Document 2 to 3

***From Supplement No. 9 to the Registration Document of JPMCFE***

Amendments to the information contained in the Registration Document 3 to 4

\* The page numbers referenced above in relation to the JPMSP 2025 Annual Report relate to the PDF version of such document, a copy of which is available on the website of the Luxembourg Stock Exchange (www.luxse.com).

\*\*The independent auditor's report (the "**auditor's report**") contained in the JPMSP 2025 Annual Report incorporated by reference into this Base Prospectus is the original auditor's report that was issued on 9 April 2026 with respect to the JPMSP 2025 Annual Report. The paragraph headed "European Single Electronic Format (ESEF)" on page 45 of the JPMSP 2025 Annual Report (PDF page 47 of the JPMSP 2025 Annual Report) relates to the official 2025 annual report of JPMSP (as prepared in XHTML format) in accordance with the applicable Regulatory Technical Standards (RTS) on ESEF, and is not applicable for the financial information and format as set out in this Base Prospectus.

\*\*\* Any charts and graphs in the page references listed in the above cross-reference table are not incorporated by reference for the purposes of the Prospectus Regulation and are included solely for informational purposes.

Any information not listed in the above cross-reference table but included in the documents referred to in the above cross-reference table is not incorporated herein by reference for the purposes of the Prospectus Regulation and is either (a) covered elsewhere in the Base Prospectus; or (b) not relevant for the investor.

## II. Amendments to the Summary of the relevant Final Terms

### 1. Amendments to the Summary of the relevant JPMSP Final Terms

The sub-section entitled "What is the key financial information regarding the Issuer?" under the section headed "Key Information on the Issuer" on each of:

- (i) pages 31 to 32 of the JPMSP Final Terms dated 24 February 2026 (ISIN: FR0014016BP6),
- (ii) pages 27 to 28 of the JPMSP Final Terms dated 17 March 2026 (ISIN: FR0014015FZ8),
- (iii) pages 21 to 22 of the JPMSP Final Terms dated 25 March 2026 (ISIN: XS3015321568),
- (iv) pages 25 to 26 of the JPMSP Final Terms dated 25 March 2026 (ISIN: FR0014015DE8),
- (v) pages 25 to 26 of the JPMSP Final Terms dated 25 March 2026 (ISIN: FR0014015DF5),
- (vi) pages 24 to 25 of the JPMSP Final Terms dated 25 March 2026 (ISIN: XS3015336087),
- (vii) page 25 of the JPMSP Final Terms dated 25 March 2026 (ISIN: FR0014016PG5);
- (viii) pages 20 to 21 of the JPMSP Final Terms dated 26 March 2026 (ISIN: SE0028329318),
- (ix) pages 21 to 22 of the JPMSP Final Terms dated 26 March 2026 (ISIN: SE0028329326),
- (x) pages 21 to 22 of the JPMSP Final Terms dated 26 March 2026 (ISIN: SE0028329342),
- (xi) pages 20 to 21 of the JPMSP Final Terms dated 26 March 2026 (ISIN: SE0028329334),
- (xii) pages 24 to 25 of the JPMSP Final Terms dated 1 April 2026 (ISIN: XS3015640157), and
- (xiii) pages 19 to 20 of the JPMSP Final Terms dated 9 April 2026 (ISIN: DE000JE2WCY0),

shall be deleted and replaced with the following:

"The following key financial information (according to IFRS) has been extracted from the audited financial statements of JPMSP for the years ended 31 December 2025 and 2024.
---

<b>Summary information – income statement</b>
---

(in USD)	Year ended 31 December 2025 (audited)	Year ended 31 December 2024 (audited)
<b>Selected income statement data</b>		
Operating loss	(774,000)	(244,000)
<b>Summary information – statement of financial position</b>		
(in USD)	As at 31 December 2025 (audited)	As at 31 December 2024 (audited)
Net financial debt (total liabilities minus cash and cash equivalents)	53,656,291,000	34,336,213,000
<b>Summary information – cash flows</b>		
(in USD)	Year ended 31 December 2025 (audited)	Year ended 31 December 2024 (audited)
Net cash used in operating activities	(1,147,574,000)	(48,944,000)
Net cash generated from financing activities	223,273,000	1,158,478,000
Net cash generated from investing activities	165,281,000	1,148,117,000"
<b><i>Qualifications in audit report on historical financial information:</i></b> There were no qualifications in the audit report with respect to the Issuer's historical financial information included herein.		

## **General**

To the extent that there is any inconsistency between (a) any statement in this Supplement or any statement incorporated by reference into the Base Prospectus by this Supplement and (b) any other statement in or incorporated by reference into the Base Prospectus, the statements in (a) above will prevail.

Investors who have not previously reviewed the information contained in the documents incorporated by reference above should do so in connection with their evaluation of the Securities.

This Supplement and the documents incorporated by reference into it will be published on the Luxembourg Stock Exchange's website at *www.luxse.com*. In addition, any person receiving a copy of this Supplement may obtain, without charge, upon written or oral request, copies of the documents incorporated by reference herein. Copies of the documents incorporated by reference into this Supplement will be available free of charge during normal business hours on any weekday (Saturdays, Sundays and public holidays excepted), in physical or electronic form, at the office of the Principal Programme Agent (The Bank of New York Mellon, London Branch, 160 Queen Victoria Street, London EC4V 4LA, United Kingdom) and the office of the Paying Agent in Luxembourg (The Bank of New York Mellon S.A./N.V., Luxembourg Branch, Vertigo Building – Polaris, 2-4 rue Eugène Ruppert, L-2453 Luxembourg).